Be the first to receive exciting updates, including offers and discounts by singing up below
Semapen is part of the Phoenix Health Group, the only private bariatric provider trusted by the NHS
We've been helping people to lose weight for more than 20 years
5-Star Rated by Trustpilot
average body weight lost in a year *
lower BMI cut off for treatment †
chance of responding to treatment
average body weight lost in a year *
lower BMI cut off for treatment †
chance of responding to treatment
After 12 months you could weigh
Results vary - weight loss can be more or less than 20% average.
Wegovy and Mounjaro are revolutionary new treatments that are clinically proven to control appetite and reduce body weight by between 15% (Wegovy) and 21% (Mounjaro)*.
But with 20 years’ experience specialising in obesity treatment, we can tell you that you’ll need more than just an injection to succeed long term. That’s where the SemaPen programme comes in.
We’ll provide you with a sleek Withings® Body smart scale (worth £60) that’s linked to our unique SemaPen app via the cloud, giving you and our support team real-time oversight of your progress.
You’ll get exclusive access to personalised support from experts in obesity care (not pharmacists or GPs). Our team of doctors, dietitians, nurses and psychologists use SemaPen’s technology to make sure you stay on track for a great outcome.
And if you’re struggling, we’re there to give you extra help with targeted feedback and advice.
We offer a free detailed online assessment you can complete at any time. This determines if you’re suitable for the treatment. There’s no need to book an online appointment or visit a clinic, GP or pharmacy.
If the SemaPen programme is right for you, we’ll discreetly send your medication and smart scales straight to your door.
Our subscription service means you don’t even have to remember to order repeat prescriptions – we take care of all that for you.
Wegovy and Mounjaro are revolutionary new treatments that are clinically proven to control appetite and reduce body weight by between 15% (Wegovy) and 21% (Mounjaro)*.
But with 20 years’ experience specialising in obesity treatment, we can tell you that you’ll need more than just an injection to succeed long term. That’s where the SemaPen programme comes in.
We’ll provide you with a sleek Withings® Body smart scale (worth £60) that’s linked to our unique SemaPen app via the cloud, giving you and our support team real-time oversight of your progress.
You’ll get exclusive access to personalised support from experts in obesity care (not pharmacists or GPs). Our team of doctors, dietitians, nurses and psychologists use SemaPen’s technology to make sure you stay on track for a great outcome.
And if you’re struggling, we’re there to give you extra help with targeted feedback and advice.
We offer a free detailed online assessment you can complete at any time. This determines if you’re suitable for the treatment. There’s no need to book an online appointment or visit a clinic, GP or pharmacy.
If the SemaPen programme is right for you, we’ll discreetly send your medication and smart scales straight to your door.
Our subscription service means you don’t even have to remember to order repeat prescriptions – we take care of all that for you.
Our free comprehensive medical consultation is designed by doctors and available 24/7. Find out in minutes if you are suitable for our programme
Order your prescription online*. No need to visit a clinic or pharmacy. Discreet delivery to your home.
*Once accepted onto the SemaPen programme
Receive a refund if you don't lose at least 5% of your starting weight after completing the 12-month SemaPen programme**
**Terms and conditions apply
You can change your mind or cancel your subscription anytime**
**Terms and conditions apply.
Here are answers to some of the most commonly asked questions about The SemaPen Programme.
For a more detailed list of FAQs, please visit Semapen FAQ Page.
How much weight will I lose?
Reputable clinical trials* found that if you use weight loss injections as part of a comprehensive weight loss programme involving dietetic support and lifestyle modification (calorie restriction and some regular exercise) an average outcome is to lose about 15% -21% of starting body weight after a year, depending upon the drug used.
It is unlikely that you will achieve this amount of weight loss with the injections alone, which is why the 12-month SemaPen programme is so important.
Remember, 15% -21% weight loss were average outcomes, but some people in the trials lost more than this and others will have lost less.
Will I lose all enjoyment of food if I use weight loss injections?
Absolutely not!
Wegovy and Mounjaro do not alter the taste of food, they work by suppressing your appetite. You will also start to feel full much sooner than normal. This dual action makes it much easier for you to avoid snacking and to control the size of your main meals.
You can still enjoy the pleasure of lovely food, but the medications put you in control, so you are able to moderate your calorie intake.
Will I have side effects?
Like all medications, Wegovy and Mounjaro may cause side effects. The most common include nausea, bloating, and constipation (sometimes accompanied by abdominal pains). This is because one of the ways weight loss injections help is by slowing down how fast the stomach and intestine empty, which contributes to a sense of early and more prolonged fullness after meals.
These symptoms are typically worse when starting treatment and for the first few days after moving up to a higher-dose pen. Most people (>95%) find them fairly easy to tolerate, particularly as they tend to improve over time. However, if they persist, it’s important to seek medical advice.
Am I suitable for The SemaPen Programme?
Wegovy and Mounjaro are approved for use in adults with a BMI of 30 or higher, although there are certain medical conditions that would make treatment inadvisable.
This BMI cut off is lowered to 27 for those who also have at least one weight-related condition. Some examples include high blood pressure, type 2 diabetes, high cholesterol, sleep apnoea, gastro-oesophageal reflux, weight-related depression or joint pain. We will ask you about this as part of the onboarding process.
People of certain ethnic origins (Asian, Black Afro-Caribbean, Arabs) are more prone to developing type 2 diabetes and cardiovascular complications of obesity at lower BMIs than Caucasians and this may be taken into account when deciding if you are suitable for treatment.
Complete our free, online medical questionnaire to determine whether you are suitable for the SemaPen programme.
Can I get it on the NHS?
Wegovy and Mounjaro have been approved for use by the NHS, but discussions are ongoing as to when they will become widely available.
In addition, NICE has recommended more stringent prescribing rules than those that apply to private patients, in that NHS patients must have a BMI greater than 35 and at least one weight-related medical condition such as type 2 diabetes* to receive NHS treatment.
It is only under exceptional circumstances that the NHS will prescribe the treatment to people with a BMI of 30-35, even if they do have medical conditions.
*https://www.nice.org.uk/news/article/nice-recommends-new-drug-for-people-living-with-obesity
Top tips to support your weight loss journey
*Wilding, J.P.H. et al. (2021) “Once-weekly semaglutide in adults with overweight or obesity,” New England Journal of Medicine, 384(11). https://doi.org/10.1056/NEJMoa2032183
**Jastreboff, A.M. et al. (2022) “Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)”New England Journal of Medicine, 215(387). DOI: 10.1056/NEJMoa2206038
† In the presence of weight related conditions, otherwise lower BMI cut-off is 30. Lower BMI threshold apply to some ethnic groups.
